Literature DB >> 8138714

Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins.

J B Swaney1, K H Weisgraber.   

Abstract

To evaluate the role of apolipoprotein (apo) C-I in inhibiting lipoprotein binding to the low density lipoprotein receptor-related protein (LRP), a putative lipoprotein remnant receptor, apoC-peptide fragments were prepared by chemical synthesis or by cyanogen bromide cleavage of intact apoC-I. In ligand-blotting assays, peptides corresponding to residues 1-38, 10-57, 20-57, 30-57, and 40-57 proved ineffective, but intact apoC-I was very effective, at inhibiting the binding of apoE-enriched beta-migrating very low density lipoproteins (beta-VLDL) to the LRP. Studies of the displacement of 125I-labeled apoE from apoE-enriched beta-VLDL showed that the largest peptide (residues 10-57) was two-thirds as effective as intact apoC-I; the other peptides were highly ineffective (residues 40-57, 1-38) or only partly effective (residues 20-57, 30-57). Changes in the intrinsic tryptophan fluorescence and helix content indicated that the largest peptide was similar to apoC-I in lipid binding affinity, while the other peptide fragments showed little or no affinity for either unilamellar or multilamellar vesicles of dimyristoyl-phosphatidylcholine. These findings suggest that the ability of apoC-I fragments to displace apoE from beta-VLDL is largely, but perhaps not exclusively, a reflection of their ability to bind to membranous bilayers and that apoC-I blocking of the interaction between apoE-rich beta-VLDL and the LRP probably involves displacement of a critical amount of the apoE from the surface of this lipoprotein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138714

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  9 in total

1.  Surface rheology and adsorption kinetics reveal the relative amphiphilicity, interfacial activity, and stability of human exchangeable apolipoproteins.

Authors:  Victor Martin Bolanos-Garcia; Anne Renault; Sylvie Beaufils
Journal:  Biophys J       Date:  2007-11-09       Impact factor: 4.033

2.  Conformational studies of the N-terminal lipid-associating domain of human apolipoprotein C-I by CD and 1H NMR spectroscopy.

Authors:  A Rozek; G W Buchko; P Kanda; R J Cushley
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

3.  In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.

Authors:  M C Jong; V E Dahlmans; P J van Gorp; K W van Dijk; M L Breuer; M H Hofker; L M Havekes
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

4.  Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor.

Authors:  M C Jong; K W van Dijk; V E Dahlmans; H Van der Boom; K Kobayashi; K Oka; G Siest; L Chan; M H Hofker; L M Havekes
Journal:  Biochem J       Date:  1999-03-01       Impact factor: 3.857

5.  Surface composition regulates clearance from plasma and triolein lipolysis of lipid emulsions.

Authors:  I Arimoto; C Matsumoto; M Tanaka; K Okuhira; H Saito; T Handa
Journal:  Lipids       Date:  1998-08       Impact factor: 1.880

6.  Apolipoprotein CI overexpression is not a relevant strategy to block cholesteryl ester transfer protein (CETP) activity in CETP transgenic mice.

Authors:  Thomas Gautier; David Masson; Miek C Jong; Jean-Paul Pais de Barros; Linda Duverneuil; Naig Le Guern; Valérie Deckert; Laure Dumont; Amandine Bataille; Zoulika Zak; Xian-Cheng Jiang; Louis M Havekes; Laurent Lagrost
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

7.  Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis.

Authors:  Richard R Almon; Debra C DuBois; Emily H Brandenburg; Wei Shi; Shuzhong Zhang; Robert M Straubinger; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-04       Impact factor: 2.745

8.  Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma.

Authors:  Jean-Paul Pais de Barros; Aurélia Boualam; Thomas Gautier; Laure Dumont; Bruno Vergès; David Masson; Laurent Lagrost
Journal:  J Lipid Res       Date:  2009-05-05       Impact factor: 5.922

9.  Gain and loss events in the evolution of the apolipoprotein family in vertebrata.

Authors:  Jia-Qian Liu; Wen-Xing Li; Jun-Juan Zheng; Qing-Nan Tian; Jing-Fei Huang; Shao-Xing Dai
Journal:  BMC Evol Biol       Date:  2019-11-13       Impact factor: 3.260

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.